stockrowCan-Fite Biopharma Ltd
CANF Healthcare Biotechnology
Can-Fite Biopharma Ltd’s revenue for fiscal 2025 (year ended December 2025) was $405,000.00, down 39.9% from fiscal 2024.
Follow CANF
Alert me
Can-Fite Biopharma Ltd (CANF) EV/Sales
As of 6 November 2026, Can-Fite Biopharma Ltd (CANF) trades at a EV/Sales of −8.7×. Over the past ten years it has ranged from −8.7× (November 2026) to 520× (November 2018); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −7.3× | — |
| FY2024 | 2.1× | 758.69% |
| FY2023 | 0.2× | (97.57%) |
| FY2022 | 10.3× | (6.15%) |
| FY2021 | 10.9× | (56.12%) |
| FY2020 | 24.9× | 1,341.55% |
| FY2019 | 1.7× | (99.58%) |
| FY2018 | 410× | 405.43% |
| FY2017 | 81.1× | 14.97% |
| FY2016 | 70.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2023 | 281× | (19.75%) |
| Jun 2023 | 350× | — |
| Mar 2023 | −4.4× | — |
| Dec 2022 | 10.3× | (19.08%) |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CANF Can-Fite Biopharma Ltd | −8.7× |
| SNTI Senti Biosciences, Inc. compare | −1.1× |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| PULM Pulmatrix, Inc. compare | 0.8× |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| CNSY Cerenome, Inc. compare | 1.5× |
| SKYE Skye Bioscience, Inc. compare | 3.6× |
| IMNN Imunon, Inc. compare | 6.2× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | 61.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)